• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Vivani Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    6/17/25 6:16:00 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $VANI alert in real time by email
    vani-20250617.htm
    false 0001266806 00012668062025-06-172025-06-17

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934


    Date of Report (Date of earliest event reported): June 17, 2025


     

    Vivani Medical, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

    Delaware   001-36747   02-0692322

    (State or Other Jurisdiction of

    Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    1350 S. Loop Road

    Alameda, California 94502

    (Address of principal executive offices, including zip code)

     

    (415) 506-8462

    (Telephone number, including area code, of agent for service)

    (Former name or former address, if changed since last report.)


     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

      Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   VANI   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




    Item 7.01. Regulation FD Disclosure

     

    The Company from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. These slides are attached to this Current Report on Form 8-K as Exhibit 99.1 and are incorporated by reference herein. The Company is also posting to the “Investors” portion of its website a copy of its current corporate slide presentation. The slides speak as of the date of this Current Report on Form 8-K. While the Company may elect to update the slides in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, the Company specifically disclaims any obligation to do so.

     

    The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act, whether made before or after the date hereof, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.


    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No. Description
    99.1   Corporate Slides as of June 17, 2025.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     



    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    VIVANI MEDICAL, INC.

     

     

     

    Date: June 17, 2025

    By:

    /s/ Donald Dwyer

     

    Name:

    Donald Dwyer

     

    Title:

    Chief Business Officer

     


    Get the next $VANI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VANI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VANI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mendelsohn Aaron

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      6/26/25 8:33:36 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Williams Gregg

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      6/26/25 7:28:12 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Baker Wilford Dean

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      6/26/25 7:27:00 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VANI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vivani Medical Appoints Anthony Baldor as Chief Financial Officer

      ALAMEDA, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of Anthony Baldor as Chief Financial Officer. Baldor succeeds Brigid A. Makes, who has decided to retire from Vivani to focus on her board appointments and personal projects after a distinguished career and significant contributions to the Company. Baldor brings more than 20 years of financial management experience in the biotechnology sector, with a proven record in fundraising, business development and corporate strategy. Prior to joining Vivani,

      6/11/25 8:00:00 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Vivani Medical to Present at the 2025 BIO International Convention

      ALAMEDA, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) (the "Company" or "Vivani"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the 2025 BIO International Convention, taking place from June 16-19, 2025 in Boston, Massachusetts. Details around Dr. Mendelsohn's presentation are as follows: Date:Wednesday, June 18, 2025Time:9:00 am, Eastern TimeLocation: Boston Convention & Exhibition Center, Room 153A   Dr. Mendelsohn will highlight Vivani's innovative, miniature drug implants, powered by its

      6/10/25 8:30:00 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders

      Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent stockholders Cortigent is developing the Orion® Visual Cortical Prosthesis System to provide meaningful visual perception to people who are blind Cortigent is developing the Stroke Recovery System to improve the recovery of arm and hand movement in people who have suffered paralysis due to stroke Spin-off will allow Vivani to focus on its continued development of miniature, ultra long-acting GLP-1 implants for chronic weight management and type 2 diabetes with annual or bi-annual dosing ALAMEDA, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Viv

      5/29/25 8:30:00 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VANI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Williams Gregg bought $12,867 worth of shares (12,740 units at $1.01) (SEC Form 4)

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      5/16/25 8:11:15 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Williams Gregg bought $1,124 worth of shares (1,113 units at $1.01) (SEC Form 4)

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      4/28/25 7:59:38 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Williams Gregg bought $1,830 worth of shares (1,812 units at $1.01) (SEC Form 4)

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      4/23/25 8:41:13 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VANI
    SEC Filings

    See more
    • Vivani Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Vivani Medical, Inc. (0001266806) (Filer)

      6/25/25 4:28:57 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Vivani Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Vivani Medical, Inc. (0001266806) (Filer)

      6/17/25 6:16:00 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Vivani Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Vivani Medical, Inc. (0001266806) (Filer)

      6/11/25 8:45:22 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VANI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Vivani Medical Inc. (Amendment)

      SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)

      5/1/23 8:42:07 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by Vivani Medical Inc.

      SC 13D - Vivani Medical, Inc. (0001266806) (Subject)

      4/25/23 5:28:48 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care